Optimi Health Launches Microdose Psilocybin
Analysis based on 12 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026
The launch of standardized microdose psilocybin products by Optimi Health Corp. is expected to positively impact the company's stock price due to expanded product offerings and increased market opportunities in clinical research and therapeutic programs. This development could also signal a growing trend in the pharmaceutical industry towards psychedelic-based mental health treatments, potentially attracting more investment into the sector.
Optimi Health Corp. has announced the completion of production and launch of two new microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. These products are naturally derived and offer consistent, validated doses for qualified, authorized clinical research organizations. This expands Optimi Health Corp.'s existing psilocybin range, which includes a 5 mg formulation already prescribed in Australia for treatment-resistant depression. The company produces these products in-house at its GMP facility in Princeton, British Columbia, Canada, under a Canada — Health Canada Drug Establishment License, and supplies them to regulated markets internationally for both patient access and clinical research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard